ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
- Status
- RECRUITING
- Phase
- PHASE4
Clinical Trials Related to Relatlimab
Related studies linked through entity extraction aliases.
Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab
- Status
- RECRUITING
- Phase
- PHASE2
Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Status
- RECRUITING
- Phase
- PHASE3
Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)
- Status
- WITHDRAWN
- Phase
- PHASE2
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
- Status
- SUSPENDED
- Phase
- PHASE2
Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab
- Status
- RECRUITING
- Phase
- PHASE2
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
- Status
- RECRUITING
- Phase
- PHASE2
Study of Relatlimab in Combination With Nivolumab in Chinese Participants
- Status
- COMPLETED
- Phase
- PHASE1
Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Expanded Access for Relatlimab
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
ARID1A and/or KDM6A Mutation and CXCL13 Expression
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML
- Status
- RECRUITING
- Phase
- PHASE2
Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2